MCL1 and acute leukemia: Despite these uncertainties, BCL-2 inhibition with venetoclax, and MCL-1 or BCL-XL inhibition potentially, represent a significant advance in targeted treatment approaches to hematologic malignancies and are very promising in acute leukemia and MDS treatment.